Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.


Journal Article (Review)

The epidermal growth factor receptor (EGFR) is a promising target in the treatment of advanced stage non-small-cell lung cancer (NSCLC). Currently erlotinib and gefitinib are approved by the US Food and Drug Administration, whereas cetuximab is being studied for use in NSCLC. Erlotinib has shown a survival advantage in patients with advanced NSCLC. Further studies have identified female sex, nonsmokers, Asian race, good performance status, and adenocarcinoma histology as predictors of patient response to these agents. A genetic mutation in EGFR has also been correlated with an increase in response.

Full Text

Duke Authors

Cited Authors

  • Byrne, BJ; Garst, J

Published Date

  • July 2005

Published In

Volume / Issue

  • 7 / 4

Start / End Page

  • 241 - 247

PubMed ID

  • 15946581

Pubmed Central ID

  • 15946581

International Standard Serial Number (ISSN)

  • 1523-3790

Digital Object Identifier (DOI)

  • 10.1007/s11912-005-0045-6


  • eng

Conference Location

  • United States